These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 21807781

  • 1. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial.
    Kume K, Amano K, Yamada S, Hatta K, Ohta H, Kuwaba N.
    J Rheumatol; 2011 Oct; 38(10):2169-71. PubMed ID: 21807781
    [Abstract] [Full Text] [Related]

  • 2. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A, Barner JC, Lawson KA, Novak S, Rascati KL, Richards KM, Harrison DJ.
    J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
    [Abstract] [Full Text] [Related]

  • 3. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
    van der Heijde D, Burmester G, Melo-Gomes J, Codreanu C, Mola EM, Pedersen R, Freundlich B, Chang DJ, Etanercept Study 400 Investigators.
    Ann Rheum Dis; 2008 Feb; 67(2):182-8. PubMed ID: 17728331
    [Abstract] [Full Text] [Related]

  • 4. Etanercept normalises left ventricular mass in patients with rheumatoid arthritis.
    Daïen CI, Fesler P, du Cailar G, Daïen V, Mura T, Dupuy AM, Cristol JP, Ribstein J, Combe B, Morel J.
    Ann Rheum Dis; 2013 Jun; 72(6):881-7. PubMed ID: 22872022
    [Abstract] [Full Text] [Related]

  • 5. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial.
    Kameda H, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, Tsukano M, Kasama T, Shiozawa S, Tanaka Y, Takeuchi T, Japan Biological Agent Study Integrated Consortium.
    Mod Rheumatol; 2010 Dec; 20(6):531-8. PubMed ID: 20574649
    [Abstract] [Full Text] [Related]

  • 6. Biological agents in monotherapy for the treatment of rheumatoid arthritis.
    Gabay C, Hasler P, Kyburz D, So A, Villiger P, von Kempis J, Walker U.
    Swiss Med Wkly; 2014 Dec; 144():w13950. PubMed ID: 24723273
    [Abstract] [Full Text] [Related]

  • 7. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial.
    van Riel PL, Freundlich B, MacPeek D, Pedersen R, Foehl JR, Singh A, ADORE Study Investigators.
    Ann Rheum Dis; 2008 Aug; 67(8):1104-10. PubMed ID: 17666447
    [Abstract] [Full Text] [Related]

  • 8. No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months.
    Mathieu S, Pereira B, Couderc M, Rabois E, Dubost JJ, Soubrier M.
    Rheumatology (Oxford); 2013 Jan; 52(1):204-9. PubMed ID: 23065359
    [Abstract] [Full Text] [Related]

  • 9. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis.
    Van Doornum S, McColl G, Wicks IP.
    Rheumatology (Oxford); 2005 Nov; 44(11):1428-32. PubMed ID: 16076882
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.
    Soini EJ, Hallinen TA, Puolakka K, Vihervaara V, Kauppi MJ.
    J Med Econ; 2012 Nov; 15(2):340-51. PubMed ID: 22168785
    [Abstract] [Full Text] [Related]

  • 11. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F, Anelli MG, Rinaldi A, Serafino L, Covelli M, Scioscia C, Iannone F, Lapadula G.
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [Abstract] [Full Text] [Related]

  • 12. Adalimumab decreases aortic stiffness independently of its effect in disease activity in patients with rheumatoid arthritis.
    Vassilopoulos D, Gravos A, Vlachopoulos C, Kandili A, Ioakeimidis N, Pectasides D, Stefanadis C.
    Clin Rheumatol; 2015 Feb; 34(2):359-64. PubMed ID: 24928345
    [Abstract] [Full Text] [Related]

  • 13. Etanercept improves inflammation-associated arterial stiffness in rheumatoid arthritis.
    Galarraga B, Khan F, Kumar P, Pullar T, Belch JJ.
    Rheumatology (Oxford); 2009 Nov; 48(11):1418-23. PubMed ID: 19734293
    [Abstract] [Full Text] [Related]

  • 14. High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.
    Daïen CI, Gailhac S, Audo R, Mura T, Hahne M, Combe B, Morel J.
    Rheumatology (Oxford); 2015 Apr; 54(4):601-8. PubMed ID: 25231180
    [Abstract] [Full Text] [Related]

  • 15. Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis.
    Carlson JJ, Ogale S, Dejonckheere F, Sullivan SD.
    Value Health; 2015 Mar; 18(2):173-9. PubMed ID: 25773552
    [Abstract] [Full Text] [Related]

  • 16. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival.
    Flouri I, Markatseli TE, Voulgari PV, Boki KA, Papadopoulos I, Settas L, Zisopoulos D, Skopouli FN, Iliopoulos A, Bertsias GK, Geborek P, Drosos AA, Boumpas DT, Sidiropoulos P.
    Semin Arthritis Rheum; 2014 Feb; 43(4):447-57. PubMed ID: 24012040
    [Abstract] [Full Text] [Related]

  • 17. Switching to the anti-interleukin-6 receptor antibody tocilizumab in rheumatoid arthritis patients refractory to antitumor necrosis factor biologics.
    Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, Arima K, Ichinose K, Kamachi M, Yamasaki S, Nakamura H, Origuchi T, Ida H, Eguchi K.
    Mod Rheumatol; 2010 Feb; 20(1):40-5. PubMed ID: 19802651
    [Abstract] [Full Text] [Related]

  • 18. Minimum effective dosages of anti-TNF in rheumatoid arthritis: a cross-sectional study.
    de la Torre I, Valor L, Nieto JC, Montoro M, Carreño L.
    Reumatol Clin; 2014 Feb; 10(2):101-4. PubMed ID: 24280444
    [Abstract] [Full Text] [Related]

  • 19. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [Abstract] [Full Text] [Related]

  • 20. Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis -- a randomized trial.
    Tam LS, Shang Q, Li EK, Wang S, Li RJ, Lee KL, Leung YY, Ying KY, Yim CW, Kun EW, Leung MH, Li M, Li TK, Zhu TY, Chui RK, Tseung L, Yu SL, Kuan WP, Yu CM.
    J Rheumatol; 2012 Dec; 39(12):2267-75. PubMed ID: 22984272
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.